Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Parry

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Medicine and Science in Sports and Exercise|April 26, 2017
Information Acquisition Differences between Experienced and Novice Time Trial CyclistsManhal Boya, Tom Foulsham, Florentina Hettinga, et al.
The British Journal of Nutrition|September 18, 2013
Dietary intake measurement using 7 d diet diaries in British men and women in the European Prospective Investigation into Cancer-Norfolk study: a focus on methodological issuesMarleen A H Lentjes, Alison McTaggart, Angela A Mulligan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2012
Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitroErin L Schenk, Brian D Koh, Karen S Flatten, et al.
Malaria Journal|September 26, 2015
Grading fluorescein angiograms in malarial retinopathyIan J C MacCormick, Richard J Maude, Nicholas A V Beare, et al.
The EMBO Journal|June 18, 2002
INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescenceSharon Brookes, Janice Rowe, Margarida Ruas, et al.
Bioorganic & Medicinal Chemistry Letters|November 25, 2010
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2Marc Labroli, Kamil Paruch, Michael P Dwyer, et al.
Bioorganic & Medicinal Chemistry Letters|November 25, 2010
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1Michael P Dwyer, Kamil Paruch, Marc Labroli, et al.
Cancer|April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapyUrsula A Matulonis, Philipp Harter, Charlie Gourley, et al.
Bioorganic & Medicinal Chemistry Letters|March 29, 2013
Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitorsXiaohua Huang, Cliff C Cheng, Thierry O Fischmann, et al.
Molecular Cancer Therapeutics|February 16, 2011
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screeningTimothy J Guzi, Kamil Paruch, Michael P Dwyer, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Medicine and Science in Sports and Exercise|April 26, 2017
Information Acquisition Differences between Experienced and Novice Time Trial CyclistsManhal Boya, Tom Foulsham, Florentina Hettinga, et al.
The British Journal of Nutrition|September 18, 2013
Dietary intake measurement using 7 d diet diaries in British men and women in the European Prospective Investigation into Cancer-Norfolk study: a focus on methodological issuesMarleen A H Lentjes, Alison McTaggart, Angela A Mulligan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2012
Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitroErin L Schenk, Brian D Koh, Karen S Flatten, et al.
Malaria Journal|September 26, 2015
Grading fluorescein angiograms in malarial retinopathyIan J C MacCormick, Richard J Maude, Nicholas A V Beare, et al.
The EMBO Journal|June 18, 2002
INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescenceSharon Brookes, Janice Rowe, Margarida Ruas, et al.
Bioorganic & Medicinal Chemistry Letters|November 25, 2010
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2Marc Labroli, Kamil Paruch, Michael P Dwyer, et al.
Bioorganic & Medicinal Chemistry Letters|November 25, 2010
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1Michael P Dwyer, Kamil Paruch, Marc Labroli, et al.
Cancer|April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapyUrsula A Matulonis, Philipp Harter, Charlie Gourley, et al.
Bioorganic & Medicinal Chemistry Letters|March 29, 2013
Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitorsXiaohua Huang, Cliff C Cheng, Thierry O Fischmann, et al.
Molecular Cancer Therapeutics|February 16, 2011
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screeningTimothy J Guzi, Kamil Paruch, Michael P Dwyer, et al.
Pageof 11